Prof. Jing Jin: National Authority in Gastrointestinal Radiation Oncology, Neoadjuvant Chemoradiotherapy & Organ Preservation at CAMS Shenzhen Hospital

Professional Profile

Prof. Jing Jin is a nationally celebrated clinical radiation oncologist, Chief Physician, Director of the Department of Radiation Oncology, and Assistant to the Hospital President at Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Hospital (CAMS Shenzhen Hospital). Honored as a "National Renowned Doctor" (国之名医), Prof. Jin is widely regarded as one of China’s foremost authorities in gastrointestinal radiation oncology, having established foundational standards that govern clinical practice nationwide.

As the principal leader and corresponding author of China’s National Guidelines for Radiation Target Delineation in Rectal Cancer, Prof. Jin has pioneered paradigm shifts in the management of locally advanced rectal cancer (LARC). His clinical leadership champions Total Neoadjuvant Therapy (TNT) and organ preservation pathways, allowing significant cohorts of clinical complete responders to avoid permanent colostomy through structured "Watch & Wait" surveillance.

Key Clinical Specializations

• National Authority in Rectal Cancer Radiotherapy: Definitive expertise in designing precision intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) for rectal adenocarcinoma, optimizing dose distribution to pelvic nodal basins while sparing bowel, bladder, and femoral structures.
• Total Neoadjuvant Therapy (TNT) & Organ Preservation: Spearheading intensified preoperative regimens combining short-course or long-course chemoradiotherapy with consolidation systemic chemotherapy and immunotherapy, dramatically enhancing pathological complete response (pCR) rates and enabling non-operative sphincter-sparing care.
• Lead Author of National Target Delineation Guidelines: Establishing the authoritative anatomic and radiological reference standards for clinical target volume (CTV) contouring in rectal cancer across China's major academic cancer centers.
• ctDNA Minimal Residual Disease (MRD) Guided Radiotherapy: Integrating longitudinal liquid biopsy profiling to detect microscopic residual disease during and after radiotherapy, enabling risk-adapted radiation boost escalation or omission.

Academic Leadership & Landmark Research (2024–2025)

With an extensive publication record exceeding 40+ high-impact SCI papers, Prof. Jing Jin continuously drives major advances in digestive radiation oncology, with recent 2024–2025 research prominently highlighted in the field’s flagship publication, the International Journal of Radiation Oncology • Biology • Physics (IJROBP) (the Red Journal):

• Landmark Publications in IJROBP (The Red Journal): Reporting multicenter randomized clinical trials on optimized sequencing for total neoadjuvant chemoradiation in locally advanced rectal cancer, establishing superior distant metastasis control and sustained organ preservation rates.
• MRD-Guided Precision Strategy Trials: Leading multicenter clinical studies utilizing circulating tumor DNA (ctDNA) dynamics to tailor adjuvant interventions, identifying patient subsets who safely avoid overtreatment after achieving complete clinical response.
• National Clinical Consensus & Committee Leadership: Serving on executive committees of the Chinese Society for Radiation Oncology (CSRO) and leading expert panels on gastrointestinal malignancies.

International Patient Coordination & Fast-Track Access

China Medical Concierge – Shanghai (CMCS) provides dedicated health management and medical concierge services connecting domestic and overseas patients with China’s premier oncology leaders. For patients seeking consultation and advanced pelvic radiotherapy planning with Prof. Jing Jin at CAMS Shenzhen Hospital, CMCS offers comprehensive support:

• Multidisciplinary second opinions on pelvic high-resolution MRI, CT simulation, and pathology reports;
• Fast-track outpatient appointments and linear accelerator simulation scheduling at CAMS Shenzhen Hospital;
• Evaluation for organ preservation feasibility and customized Total Neoadjuvant Therapy (TNT) clinical trials;
• Full-course medical translation, bilingual patient accompaniment, and longitudinal radiation follow-up care.